News

2016

company

year

domain

Syros Pharmaceuticals Presents Data Demonstrating Significant Anti - Cancer Activity of SY - 1425 in Preclinical Models of Acute Myeloid Leukemia

Syros Pharmaceuticals 04.18.2016

Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking

Avedro 04.18.2016

Seventh Sense Biosystems Launches Pivotal Trial For Groundbreaking TAP Diagnostic Blood Collection Device

YourBio Health 04.13.2016

UChicago and Evelo Biosciences sign licensing deal for microbiome-based cancer immunotherapy

Evelo Biosciences 04.07.2016

Editas Medicine Reports Fourth Quarter and Full Year 2015 Financial Results

Editas Medicine 03.30.2016

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA® (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy

Agios Pharmaceuticals 03.30.2016

Moderna Therapeutics Appoints Saqib Islam as Chief Business Officer

Moderna 03.28.2016

Quanterix Raises $46 Million in Series D Financing

Quanterix 03.23.2016

BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS® Platform

BIND Therapeutics 03.15.2016

Publication in Science Further Validates Importance of Gene Control Research in Yielding New Insights into Diagnosing and Treating Cancer

Syros Pharmaceuticals 03.03.2016

Loading